Estudo randomizado | Balovaptam não é melhor que placebo para a comunicação social no transtorno do espectro autista infantil.

Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial – JAMA Psychiatry

Comentário no Twitter

In this RCT, balovaptan did not demonstrate efficacy in improvement of socialization and communication in pediatric autism spectrum disorder (ASD), highlighting challenges faced in #ASD trial design, such as outcome measure sensitivity & placebo response. https://t.co/FFAJeu5xv0

— JAMA Psychiatry (@JAMAPsych) July 6, 2022